Equities

Champions Oncology Inc

Champions Oncology Inc

Actions
Health CareHealth Care Providers
  • Price (USD)4.64
  • Today's Change0.13 / 2.88%
  • Shares traded5.92k
  • 1 Year change-16.85%
  • Beta0.5121
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Champions Oncology Inc share price to rise to 6.00 in the next year from the last price of 4.64.
High29.3%6.00
Med29.3%6.00
Low29.3%6.00

Earnings history & estimates in USD

On Sep 11, 2024, Champions Oncology Inc reported 1st quarter 2025 earnings of 0.11 per share. This result exceeded the -0.03 consensus loss of the one analyst covering the company and outperformed last year's 1st quarter results by 0.270.
The next earnings announcement is expected on Dec 10, 2024.
Average growth rate+333.19%
Champions Oncology Inc reported annual 2024 losses of -0.46 per share on Jul 18, 2024.
Average growth rate+41.03%
More ▼

Revenue history & estimates in USD

Champions Oncology, Inc. had 1st quarter 2025 revenues of 14.06m. This bettered the 13.23m estimate of the one analyst covering the company. This was 11.94% above the prior year's 1st quarter results.
Average growth rate+3.23%
Champions Oncology, Inc. had revenues for the full year 2024 of 50.16m. This was 6.90% below the prior year's results.
Average growth rate+12.55%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.